Protein detail
CD47
Leukocyte surface antigen CD47 (Antigenic surface determinant protein OA3) (Integrin-associated protein) (IAP) (Protein MER6) (CD antigen CD47)
Entry name CD47 | UniProt ID | EVMP confidence score 0.88 |
Supporting publications (n) 29 | Transmembrane count 5 | Protein classification CD markersPredicted intracellular proteinsPredicted membrane proteinsTransporters |
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40Basic Information13
Protein Names
Leukocyte surface antigen CD47 (Antigenic surface determinant protein OA3) (Integrin-associated protein) (IAP) (Protein MER6) (CD antigen CD47)
Protein Class (4)
CD markersPredicted intracellular proteinsPredicted membrane proteinsTransporters
Protein Function (3)
- Transporters:Transporter channels and pores
- CD markers
- Predicted intracellular proteins
Transmembrane
142..162; Helical; 177..197; Helical; 208..228; Helical; 236..256; Helical; 269..289; Helical
Transmembrane Count
5
Ensembl
Entrez Gene Symbol
Gene Synonym (3)
IAPMER6OA3
Gene Description
CD47 molecule
Chromosome
3
Position
108043091-108091862
Supporting publications (n)
29
EVMP confidence score
0.88
Fluorescence & Localization6
Tissue Specificadipose tissueCell SpecificMegakaryocytesSingle-Nuclei Brain Specificendothelial cellBlood Cell SpecificbasophilBlood Lineage Specificgranulocytes
Function & Pathway7
Protein Function (3)
- Transporters:Transporter channels and pores
- CD markers
- Predicted intracellular proteins
Cellular Component (5)
Molecular Function (5)
Biological Process (3)
Reactome (8)
- R-hsa-1500931 cell cell communication
- R-hsa-202733 cell surface interactions at the vascular wall
- R-hsa-1474244 extracellular matrix organization
- R-hsa-109582 hemostasis
- R-hsa-168249 innate immune system
- R-hsa-216083 integrin cell surface interactions
- R-hsa-6798695 neutrophil degranulation
- R-hsa-391160 signal regulatory protein family interactions
Mediation Categories (5)
Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation
Relations & Evidence56
Ligand-Receptor Signaling (54)
54 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | CellPhoneDB | No | Yes | No | Yes | No |
| receptor | receptor | GO_Intercell | No | Yes | No | Yes | No |
| receptor | receptor | HPMR | No | Yes | No | Yes | No |
| receptor | receptor | ICELLNET | No | Yes | No | Yes | No |
| receptor | receptor | CellChatDB | No | Yes | No | Yes | No |
| receptor | receptor | CellTalkDB | No | Yes | No | Yes | No |
| receptor | receptor | Ramilowski2015 | No | Yes | No | Yes | No |
| receptor | receptor | Guide2Pharma | No | Yes | No | Yes | No |
| receptor | receptor | LRdb | No | Yes | No | Yes | No |
| other_receptor_family | receptor | HPMR | No | Yes | No | Yes | No |
Page 1 of 6Next
Regulatory Interaction Network (1)
1 record.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| TSP2 | P35442 | CD47 | Q08722 | Yes | Yes | No | CellChatDBFantom5_LRdbCellTalkDBHPMR_LRdbiTALKHPMR_CellinkertalklrRamilowski2015SIGNORconnectomeDB2020UniProt_LRdbCellinkerWangLRdbHPMR_talklr | Cellinker:8550562LRdb:8550562connectomeDB2020:8550562CellTalkDB:8550562SIGNOR:8550562 |
Isolation & Detection Technology (1)
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential Ultracentrifugation | Mass spectrometry | 1 | 37438638 |
Sequence, Structure & Domains10
Sequences
Length
323
Mass
35,214
Sequence
MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRKAVEEPLNAFKESKGMMNDE
Alternative Products
Event=Alternative splicing; Named isoforms=4; Name=OA3-323; IsoId=Q08722-1; Sequence=Displayed; Name=OA3-293; IsoId=Q08722-2; Sequence=VSP_002535; Name=OA3-305; IsoId=Q08722-3; Sequence=VSP_002536, VSP_002537; Name=OA3-312; IsoId=Q08722-4; Sequence=VSP_002538
Alternative Sequence
293..323; Missing (in isoform OA3-293); 304..305; KA -> NN (in isoform OA3-305); 306..323; Missing (in isoform OA3-305); 312..323; Missing (in isoform OA3-312)
3D Structural Models
Turn
139..143; 254..260
Helix
51..53; 70..72; 79..81; 88..93; 102..106; 144..164; 178..196; 204..224; 238..253; 268..292
Beta Strand
26..30; 35..39; 42..45; 54..60; 63..69; 74..76; 98..101; 110..118; 121..131; 197..202; 261..264
3D Structure
X-ray crystallography (15)
Domain & Motif Annotations
Domain (FT)
19..127; Ig-like V-type
Clinical Relevance4
Related Diseases (17)
Acute myeloid leukaemiaB-cell lymphomaColorectal cancerDiffuse large B-cell lymphomaLeukaemiaLymphomaMalignant haematopoietic neoplasmMelanomaMultiple myelomaMycosis fungoidesMyelodysplastic syndromeNeuroendocrine carcinomaNon-small-cell lung cancerOvarian cancerSolid tumour/cancerSquamous cell carcinomaStomach cancer
Biomarker
Phase 1; Phase 1/2; Phase 2; Phase 3; Phase 2/3
Supporting Publications29
| PMID | Title | Abstract |
|---|---|---|
| 35078498 | Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. | Bioinspired hybrid nanoparticles formed by the fusion of CD47-expressing tumor exosomes and cRGD-modified liposomes (miR497/TP-HENPs) were prepared to codeliver miR497 and TP. |
| 36107309 | Single vesicle analysis of CD47 association with integrins and tetraspanins on extracellular vesicles released by T lymphoblast and prostate carcinoma cells. | No abstract available |
| 36162554 | Advantage of extracellular vesicles in hindering the CD47 signal for cancer immunotherapy. | To develop a safe and potent CD47 blockade, we designed extracellular vesicles (EVs) harboring signal regulatory protein alpha (SIPRα)-EV-SIRPα (EVs that express SIPRα). |
| 36353645 | Extracellular vesicles from pristane-treated CD38-deficient mice express an anti-inflammatory neutrophil protein signature, which reflects the mild lupus severity elicited in these mice. | No abstract available |
| 36454036 | CD47 cross-dressing by extracellular vesicles expressing CD47 inhibits phagocytosis without transmitting cell death signals. | No abstract available |
| 37384818 | Extracellular Vesicles-Derived Hybrid Nanoplatforms for Amplified CD47 Blockade-Based Cancer Immunotherapy. | No abstract available |
| 38431093 | Smart exosomes enhance PDAC targeted therapy. | To overcome these limitations, we developed "Smart Exosomes" that co-display RGD and CD47 Published by Elsevier B.V. |
| 38439112 | Docosahexaenoic acid (DHA) impairs hypoxia-induced cellular and exosomal overexpression of immune-checkpoints and immunomodulatory molecules in different subtypes of breast cancer cells. | MDA-MB-231 and BT-474 cells were treated with 100 µM DHA under hypoxic and normoxic conditions for 24 h. Exosomes were isolated by ultracentrifuge and confirmed by electron microscope and anti-CD9, -CD63, -CD81 immunoblotting. Total RNA from cells and exosomes were extracted and expression of CD39, CD73, CD47, CD80, PD-L1, B7-H3, B7-H4 genes and their related miRs were evaluated by quantitative Real-time PCR. |
| 38749193 | CD47-mediated immune evasion in early-stage lung cancer progression. | Abundant CD47 was observed in the cytoplasm of lung cancer cells, aligning with our finding that it was packed into extracellular vesicles for physiological and pathological functions. In our clinical cohort, extracellular vesicle CD47 was significantly higher in the patients with early-stage lung cancer, emphasizing innate immunity inactivation in early tumor progression. In this study, we demonstrated that CD47 is not only a transmembrane protein, but that it is also highly concentrated in extracellular vesicles from lung cancer cell lines and patient plasma. |
Page 3 of 3Previous